Capital Planning Advisors LLC Purchases Shares of 5,203 Eli Lilly and Company (LLY)

Capital Planning Advisors LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,203 shares of the company’s stock, valued at approximately $428,000.

A number of other large investors also recently made changes to their positions in LLY. BlackRock Inc. lifted its holdings in Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after acquiring an additional 59,978,664 shares during the period. Vanguard Group Inc. increased its position in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after buying an additional 2,181,701 shares in the last quarter. Winslow Capital Management LLC increased its position in shares of Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after buying an additional 1,719,538 shares in the last quarter. Harbour Capital Advisors LLC increased its position in shares of Eli Lilly and by 7,919.1% in the second quarter. Harbour Capital Advisors LLC now owns 1,705,338 shares of the company’s stock valued at $20,721,000 after buying an additional 1,684,072 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after buying an additional 1,441,200 shares in the last quarter. 75.53% of the stock is owned by institutional investors.

WARNING: “Capital Planning Advisors LLC Purchases Shares of 5,203 Eli Lilly and Company (LLY)” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://transcriptdaily.com/2017/10/23/capital-planning-advisors-llc-purchases-shares-of-5203-eli-lilly-and-company-lly.html.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 990,000 shares of company stock valued at $82,949,650 in the last three months. 0.20% of the stock is currently owned by company insiders.

LLY has been the subject of a number of recent analyst reports. UBS AG cut Eli Lilly and to a “hold” rating and set a $85.00 price objective for the company. in a research report on Wednesday, July 26th. BMO Capital Markets restated a “sell” rating and issued a $71.00 price objective on shares of Eli Lilly and in a research report on Thursday, September 28th. Morgan Stanley set a $86.00 price objective on Eli Lilly and and gave the company a “hold” rating in a research report on Friday, October 6th. Piper Jaffray Companies restated a “buy” rating and issued a $105.00 price objective on shares of Eli Lilly and in a research report on Friday, October 13th. Finally, Berenberg Bank restated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research report on Friday, August 4th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $88.97.

Shares of Eli Lilly and Company (LLY) opened at 87.23 on Monday. Eli Lilly and Company has a one year low of $64.18 and a one year high of $89.09. The stock has a market capitalization of $92.03 billion, a PE ratio of 37.75 and a beta of 0.34. The firm has a 50-day moving average price of $84.38 and a 200 day moving average price of $82.29.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.86 earnings per share. On average, equities analysts expect that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.38%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s payout ratio is 90.04%.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply